Literature DB >> 31471584

MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer.

Xiao Lu1, Rui Liu1, Meina Wang1, Alagamuthu Karthick Kumar1, Feiyan Pan1, Lingfeng He1, Zhigang Hu2, Zhigang Guo3.   

Abstract

An increased DNA repair capacity is associated with drug resistance and limits the efficacy of chemotherapy in breast cancers. Flap endonuclease 1 (FEN1) participates in various DNA repair pathways and contributes to cancer progression and drug resistance in chemotherapy. Inhibition of FEN1 serves as a potent strategy for cancer therapy. Here, we demonstrate that microRNA-140 (miR-140) inhibits FEN1 expression via directly binding to its 3' untranslated region, leading to impaired DNA repair and repressed breast cancer progression. Overexpression of miR-140 sensitizes breast cancer cells to chemotherapeutic agents and overcomes drug resistance in breast cancer. Notably, ectopic expression of FEN1 abates the effects of miR-140 on DNA damage and the chemotherapy response in breast cancer cells. Furthermore, the transcription factor/repressor Ying Yang 1 (YY1) directly binds to the miR-140 promoter and activates miR-140 expression, which is attenuated in doxorubicin resistance. Our results demonstrate that miR-140 acts as a tumor suppressor in breast cancer by inhibiting FEN1 to repress DNA damage repair and reveal miR-140 to be a new anti-tumorigenesis factor for adjunctive breast cancer therapy. This novel mechanism will enhance the treatment effect of chemotherapy in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31471584     DOI: 10.1038/s41388-019-0986-0

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  40 in total

1.  Predicted poxvirus FEN1-like nuclease required for homologous recombination, double-strand break repair and full-size genome formation.

Authors:  Tatiana G Senkevich; Eugene V Koonin; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-01       Impact factor: 11.205

Review 2.  The DNA-damage response in human biology and disease.

Authors:  Stephen P Jackson; Jiri Bartek
Journal:  Nature       Date:  2009-10-22       Impact factor: 49.962

Review 3.  Endogenous DNA Damage as a Source of Genomic Instability in Cancer.

Authors:  Anthony Tubbs; André Nussenzweig
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

4.  Processing of UV damage in vitro by FEN-1 proteins as part of an alternative DNA excision repair pathway.

Authors:  J H Yoon; P M Swiderski; B E Kaplan; M Takao; A Yasui; B Shen; G P Pfeifer
Journal:  Biochemistry       Date:  1999-04-13       Impact factor: 3.162

5.  A role for FEN-1 in nonhomologous DNA end joining: the order of strand annealing and nucleolytic processing events.

Authors:  X Wu; T E Wilson; M R Lieber
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

Review 6.  Flap endonuclease 1.

Authors:  Lata Balakrishnan; Robert A Bambara
Journal:  Annu Rev Biochem       Date:  2013-02-28       Impact factor: 23.643

Review 7.  Targeting the DNA Damage Response in Cancer.

Authors:  Mark J O'Connor
Journal:  Mol Cell       Date:  2015-11-19       Impact factor: 17.970

Review 8.  Functional regulation of FEN1 nuclease and its link to cancer.

Authors:  Li Zheng; Jia Jia; L David Finger; Zhigang Guo; Cindy Zer; Binghui Shen
Journal:  Nucleic Acids Res       Date:  2010-10-06       Impact factor: 16.971

9.  Targeting DNA Flap Endonuclease 1 to Impede Breast Cancer Progression.

Authors:  Lingfeng He; Yilan Zhang; Hongfang Sun; Feng Jiang; Huan Yang; Huan Wu; Ting Zhou; Sencai Hu; Chandra Sekhar Kathera; Xiaojun Wang; Haoyan Chen; Hongzhi Li; Binghui Shen; Yongqiang Zhu; Zhigang Guo
Journal:  EBioMedicine       Date:  2016-11-10       Impact factor: 8.143

10.  FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer.

Authors:  Lingfeng He; Libo Luo; Hong Zhu; Huan Yang; Yilan Zhang; Huan Wu; Hongfang Sun; Feng Jiang; Chandra S Kathera; Lingjie Liu; Ziheng Zhuang; Haoyan Chen; Feiyan Pan; Zhigang Hu; Jing Zhang; Zhigang Guo
Journal:  Mol Oncol       Date:  2017-05-12       Impact factor: 6.603

View more
  22 in total

1.  Long transcripts minus touchdown qPCR (LTMT-qPCR): a simplified and convenient method for the screening and quantification of microRNA profiles.

Authors:  Xi Wang; Yixiao Feng; Shixian Zhou; Xiaorong Yang; Yan Liu; Qi Peng; Xuehua Kong; Lan Zhou; Zongyue Zeng
Journal:  Lab Invest       Date:  2021-08-10       Impact factor: 5.662

Review 2.  Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism.

Authors:  J Wei; Z Liu; J He; Q Liu; Y Lu; S He; B Yuan; J Zhang; Y Ding
Journal:  Clin Transl Oncol       Date:  2021-10-13       Impact factor: 3.405

Review 3.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

4.  METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis.

Authors:  Enjie Li; Mingyue Xia; Yu Du; Kaili Long; Feng Ji; Feiyan Pan; Lingfeng He; Zhigang Hu; Zhigang Guo
Journal:  Elife       Date:  2022-05-03       Impact factor: 8.713

5.  YY1 as a promoter regulating the circ_0001946/miR-671-5p/EGFR axis to promote chemotherapy resistance in breast cancer cells.

Authors:  Ge Gao; Xiaoyan Li; Jiabeini Zhang; Hong Yu
Journal:  Am J Transl Res       Date:  2022-04-15       Impact factor: 3.940

Review 6.  MicroRNAs as the critical regulators of Doxorubicin resistance in breast tumor cells.

Authors:  Amir Sadra Zangouei; Maliheh Alimardani; Meysam Moghbeli
Journal:  Cancer Cell Int       Date:  2021-04-15       Impact factor: 5.722

7.  Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer.

Authors:  Kaili Long; Lili Gu; Lulu Li; Ziyu Zhang; Enjie Li; Yilan Zhang; Lingfeng He; Feiyan Pan; Zhigang Guo; Zhigang Hu
Journal:  Cell Death Dis       Date:  2021-05-18       Impact factor: 8.469

Review 8.  The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.

Authors:  Mingyue Xia; Zhigang Guo; Zhigang Hu
Journal:  Biomolecules       Date:  2021-05-12

Review 9.  The Two Sides of YY1 in Cancer: A Friend and a Foe.

Authors:  Sailu Sarvagalla; Srinivasa Prasad Kolapalli; Sivakumar Vallabhapurapu
Journal:  Front Oncol       Date:  2019-11-20       Impact factor: 6.244

Review 10.  The biological implications of Yin Yang 1 in the hallmarks of cancer.

Authors:  Ian Timothy Sembiring Meliala; Rendy Hosea; Vivi Kasim; Shourong Wu
Journal:  Theranostics       Date:  2020-03-04       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.